ECS Botanics (ASX:ECS) - Executive Director, Nan Maree Schoerie
Executive Director, Nan Maree Schoerie
Source: ECS Botanics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ECS Botanics (ECS) secures a four year agreement with one of New Zealand’s largest cannabis distribution companies
  • The new deal with MW Pharma will see the company supply ECS medicinal cannabis products, generating a minimum $1.5 million in revenue
  • The product will be white labelled across existing brands and sold through MW Pharma’s relationships with New Zealand’s pharmacy networks, with first supply anticipated in early 2022
  • ECS says it aims to increase the sale of its cannabis production this season, with several additional contracts in their final stages
  • ECS Botanics was up 2.94 per cent, trading at 3.5 cents at 1:45 pm AEST

ECS Botanics (ECS) has secured a four year agreement with one of New Zealand’s largest cannabis distribution companies.

A new deal with MW Pharma will see the company supply ECS medicinal cannabis products, generating a minimum of $1.5 million in revenue.

The product will be white labelled across existing brands and sold through MW Pharma’s established relationships with New Zealand’s pharmacy networks.

Under the deal, the minimum order value will be $250,000 with a minimum $500,000 over the following three years. The first supply is set to begin in early 2022 following registration of the products.

The companies have agreed to individual purchase orders of a minimum of $30,000, with minimum order quantities applying for the first 12 months.

ECS said it aimed to increase the sale of its cannabis production this season, with several additional contracts in their final stages.

“As the coming season approaches, we look forward to scaling our supply to meet our customer needs across Australia and international markets,” Executive Director Nan-Maree Schoerie said.

ECS Botanics was up 2.94 per cent, trading at 3.5 cents at 1:45 pm AEST.

ECS by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars